Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Terapia combinada para el tratamiento del cáncer

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20160210001
Publicado:
29/02/2016
Caducidad:
28/02/2017
Resumen:
Un equipo de investigación multidisciplinar de Cataluña con experiencia en metabolómica ha descubierto una combinación sinergética de medicamentos para el tratamiento del cáncer. Esta terapia combinada se basa en la inhibición de proteínas clave asociadas a la desregulación del ciclo celular y permite la letalidad selectiva de células tumorales. El equipo de investigación busca compañías farmacéuticas y biotecnológicas con el fin de establecer acuerdos de licencia para continuar con el desarrollo de la tecnología, aunque está abierto a otras colaboraciones.

Details

Tittle:
Combination therapy for the treatment of cancer
Summary:
A Catalan multidisciplinary research group experienced on metabolomics has discovered a synergistic combination of drugs for the treatment of cancer. This combination therapy is focused on the inhibition of key proteins associated to cell cycle deregulation and allowing for a selective lethality to tumour cells.
The group is looking for a pharmaceutical and biotech companies for license agreement to further develop the technology, but other collaborations may be considered.
Description:
Genes related to cell cycle control are frequently overexpressed in cancer, so they are promising targets for the inhibition of cell cycle progression. However, little is known of metabolic consequences associated to this deregulation.
In cancer, metabolic pathways are modified as a consequence of tumor reprogramming to a more convenient metabolic state. As a consequence, central-metabolism enzymes have their activities changed, providing the evidence that regulatory components could be fundamental for the maintenance of the tumor metabolic state and highlighting potential targets for cancer therapy.
One of the big problems in cancer treatment is the difficulty of selective toxicity. The combination of an inhibitor targeting cell cycle progression and another one focusing on reprogrammed metabolic-regulatory factors might selectively target tumor cells.
Until now cancer therapies have made separate use of cell cycle and metabolic enzyme inhibitors.
The research group from Catalan university has a wide experience on metabolomics analysis and the evaluation of antitumoral compounds. The group has focused on a therapeutic strategy combining both inhibitors (cell cycle and metabolic enzyme inhibitors), resulting on synergistic and selective effects on tumor cells.
Cell proliferation assays and tumor spheroids formation assays have been performed in order to validate the effectiveness of both drugs, combined and separately. There is an ongoing development plan to confirm the synergy of the combination therapy in in vivo assay.
The present discovery provides a combined therapy with improved results on the inhibition of cancer cell growth and a less effect on the healthy ones.
The group is looking for biotech and pharmaceutical companies focused in the development of oncology therapy for license agreement to carry on with the preclinical and clinical phases.
Advantages and Innovations:
- This combination therapy could overcome adaptive resistance to cell cycle inhibitors.

- This therapy could be a good strategy to reduce the chemotherapy dose and its toxicity in cancer patients.

- This therapy has selective antiproliferative effects on cancer cells.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Priority patent application filed August 2015

Partner sought

Type and Role of Partner Sought:
- Type of partner sought: Biotech and pharmaceutical companies.

- Specific area of activity of the partner: oncology

- Task to be performed by the partner sought: perform pre-clinical assays and carry on with the clinical phase.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06001003 Citología, cancerología, oncología
06001015 Productos farmacéuticos / medicamentos